RNAi drug specialist ADARx raises $446M IPO

1 source ·1 article ·2h ago Atrium Therapeutics

ADARx is the only maker of RNA-based drugs to go public since 2024 and the first RNAi biotech to price an IPO in the U.S. in more than a decade.

Covered by 1 outlet

All coverage · 1 article

ADARx is the only maker of RNA-based drugs to go public since 2024 and the first RNAi biotech to price an IPO in the U.S. in more than a decade.